Artificial intelligence and high-quality development in pharmaceutical manufacturing: evidence and mechanisms from Chinese listed firms

Introduction As a strategic industry, pharmaceutical manufacturing bears not only on industrial economic development but also on the stability of drug supply and the resilience of public health systems. Yet the industry has long been constrained by heavy R&D investment, long development cycles, and low success rates, together with mounting quality-control pressure and rapidly growing public health needs. Artificial intelligence (AI) offers a promising route for easing these bottlenecks. Methods Using a sample of pharmaceutical manufacturing firms listed on China’s Shanghai and Shenzhen A-share markets from 2007 to 2024, this study constructs a firm-level index of high-quality development and examines how AI application is related to the high-quality development of pharmaceutical firms and through what channels. Results We find that AI application is significantly and positively associated with the high-quality development of listed pharmaceutical firms. This association is robust to alternative measures of AI, an instrumental-variable strategy, propensity score matching, lagged explanatory variables, and an index that excludes the development-scale dimension. Channel analyses suggest two routes: AI application is associated with stronger access to policy resources, measured by government subsidies, and with a higher share of highly skilled employees. Heterogeneity analyses show that the positive association is significant across life-cycle stages, regions, and ownership structures, with larger coefficients for mature firms and for firms in central and western China. Discussion This study provides firm-level evidence on AI application in pharmaceutical manufacturing and offers implications for policy design and technology strategies across firms.

Authors

Institutions

Publication Details

Journal
Frontiers in Public Health
Published
2026-11-13
DOI
https://doi.org/10.3389/fpubh.2026.1998133
Primary Topic
Firm Innovation and Growth
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Artificial intelligence and high-quality development in pharmaceutical manufacturing: evidence and mechanisms from Chinese listed firms

Yanan Zhu, Yuwen Chen, Qiang Liu
4 links
Frontiers in Public Health
Firm Innovation and Growth
article

Artificial intelligence and high-quality development in pharmaceutical manufacturing: evidence and mechanisms from Chinese listed firms

Yanan Zhu, Yuwen Chen, Qiang Liu
article en

Abstract

Introduction As a strategic industry, pharmaceutical manufacturing bears not only on industrial economic development but also on the stability of drug supply and the resilience of public health systems. Yet the industry has long been constrained by heavy R&D investment, long development cycles, and low success rates, together with mounting quality-control pressure and rapidly growing public health needs. Artificial intelligence (AI) offers a promising route for easing these bottlenecks. Methods Using a sample of pharmaceutical manufacturing firms listed on China’s Shanghai and Shenzhen A-share markets from 2007 to 2024, this study constructs a firm-level index of high-quality development and examines how AI application is related to the high-quality development of pharmaceutical firms and through what channels. Results We find that AI application is significantly and positively associated with the high-quality development of listed pharmaceutical firms. This association is robust to alternative measures of AI, an instrumental-variable strategy, propensity score matching, lagged explanatory variables, and an index that excludes the development-scale dimension. Channel analyses suggest two routes: AI application is associated with stronger access to policy resources, measured by government subsidies, and with a higher share of highly skilled employees. Heterogeneity analyses show that the positive association is significant across life-cycle stages, regions, and ownership structures, with larger coefficients for mature firms and for firms in central and western China. Discussion This study provides firm-level evidence on AI application in pharmaceutical manufacturing and offers implications for policy design and technology strategies across firms.

Frontiers in Public HealthVol. 14
Shenyang Pharmaceutical University (CN)
Industry, innovation and infrastructure, Good health and well-being
Firm Innovation and Growth
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon